Download full-text PDF

Source

Publication Analysis

Top Keywords

[insulinoma aged
4
aged patients]
4
[insulinoma
1
patients]
1

Similar Publications

Background: Pancreatic neuroendocrine tumors (PNETs) are uncommon and heterogeneous neoplasms, often exhibiting indolent biological behavior. Their incidence is rising, largely due to the widespread use of high-resolution imaging techniques, particularly influencing the diagnosis of sporadic non-functioning tumors, which account for up to 80% of cases. While surgical resection remains the only curative option, the impact of factors such as tumor grade, size, and type on prognosis and recurrence is still unclear.

View Article and Find Full Text PDF

Introduction: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical symptoms. The European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) represents a pioneering effort to advance early detection of type 1 diabetes through public health screening.

View Article and Find Full Text PDF
Article Synopsis
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can be either hormone-secreting or non-secreting, have serious health implications, and an average survival of 75-124 months.
  • Research shows that key genes involved in the tumor's development, especially epigenetic regulators like MEN1, DAXX, and ATRX, are often mutated, but their effects are not well understood.
  • The calcium sensing receptor (CaSR) is significantly reduced in GEP-NETs, potentially due to DNA methylation and chromatin modifications, suggesting it functions as a tumor suppressor by inhibiting cell growth in pancreatic NETs.
View Article and Find Full Text PDF

Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.

Clin Nucl Med

January 2025

From the Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Article Synopsis
  • A study was conducted to compare a new GLP-1R-targeted PET agent, 68 Ga-HBED-CC-exendin-4, with an older version, 68 Ga-NOTA-exendin-4, for locating insulinoma in patients with hyperinsulinemic hypoglycemia.
  • Both agents demonstrated 100% sensitivity, but 68 Ga-HBED-CC-exendin-4 had a lower tumor uptake value compared to 68 Ga-NOTA-exendin-4, although both maintained similar tumor-to-background ratios.
  • The new agent also showed a significant reduction in renal accumulation, potentially enhancing the detection of tumors located near the kidney.
View Article and Find Full Text PDF
Article Synopsis
  • * A study was conducted on 9 patients with unexplained high insulin levels, where a calcium stimulation test helped target the insulinoma to specific areas of the pancreas, which standard imaging couldn't identify.
  • * Results showed increased insulin levels in 5 patients post-test, confirming the presence of insulinomas or nesidioblastosis in several cases, while some patients were treated medically instead of surgically.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!